Huseyin Salih Semiz

Prof. Dr. Huseyin Salih Semiz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
MKMerve Keskinkılıç
Merve Keskinkılıç
HSHuseyin Salih Semiz
Huseyin Salih Semiz
EAEvrim Ataca
Evrim Ataca
TYTugba Yavuzsen
Tugba Yavuzsen
Backround and purpose: A low Prognostic Nutritional Index (PNI) value, which reflects immune nutrition and inflammation around the tumor, is associated with an unfavorable prognosis, and it was aimed to reveal its prognostic value in metastatic colorectal cancer (CRC). Methods: In our retrospective cross-sectional study, patients with a diagnosis of metastatic colorectal disease without active infection, between January 2010 and December 2016 were included. The PNI values at the time of diagnosis were calculated according to the formula (10 × serum albumin (g/dL)) + (0.005 × total lymphocyte value). Results: The mean PNI value of 253 patients included in the study was 46.6. While 53.75% (n = 136) of the patients had a PNI value of 46.6 and above, 46.25% (n = 117) had a PNI value below 46.6. The overall survival (OS) of the group with a PNI of 46.6 and above was statistically significantly longer (53.06 months vs 38.80 months, p = 0.039). The PFS duration of the group with PNI below 46.6 was 25.66 months, while the PFS duration of the group with PNI above 46.6 was not reached (p = 0.265). Conclusion: PNI is a simple and inexpensive index that evaluates the immunonutritional status, and it is a prognostic marker that can be easily used in patients with metastatic colorectal cancer as in other cancer types.

22 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HEHalil İbrahim Ellez
Halil İbrahim Ellez
MKMerve Keskinkılıç
Merve Keskinkılıç
HSHuseyin Salih Semiz
Huseyin Salih Semiz
Mehmet Emin ArayiciMehmet Emin Arayici
Mehmet Emin Arayici
EKErdem Kısa
Erdem Kısa
IOIlhan Oztop
Ilhan Oztop
Prognostic nutritional index (PNI), which is calculated using the albumin level reflecting nutritional status and lymphocyte count reflecting immune status, is useful in showing nutritional and immunological status related to survival and prognosis in many cancers. In this study, we aimed to evaluate the biomarker potential and effect of PNI in determining the prognosis of metastatic castration-sensitive prostate cancer (mCSPC). This retrospective observational study included the complete data of 108 patients with mCPSC who were treated for at least three months between 1 January 2010, and 1 June 2021. The relationships between cancer-specific survival (CSS), overall survival (OS), progression-free survival (PFS), and PNI were evaluated. The Kaplan–Meier method for OS, PFS, and CSS, as well as univariate and multivariate Cox regression models, were used for the statistical analyses. The median age of 108 patients included in the study was 68.54 (61.05–74.19) years. A value of 49.75 was determined to be the best cut-off point for the PNI. OS (months) was found to be significantly lower in patients with low PNI (median: 34.93, 95% CI: 21.52–48.34) than in patients with high PNI (median: 65.60, 95% CI: 39.36–91.83) (p = 0.016). Patients with high PNI (median: 48.20, 95% CI: 34.66–61.73) had significantly better CSS (months) than patients with low PNI (median: 27.86, 95% CI: 24.16–31.57) (p = 0.001). There was no statistically significant difference in PFS between patients with high PNI values (median: 24.60, 95% CI: 10.15–39.05) and patients with low PNI values (median: 20.03, 95% CI: 11.06–29.03) (p = 0.092). The PNI is a good predictor of OS and CSS in patients with mCSPC. The prediction of PFS, albeit showing a trend towards significance, was not statistically significant, probably due to the small number of cases.

5 October 2022 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
BMBerke Manoğlu
Berke Manoğlu
SSSelman Sökmen
Selman Sökmen
TBT. Bisgin
T. Bisgin
HSHuseyin Salih Semiz
Huseyin Salih Semiz
IGİ. B. Görken
İ. B. Görken
HEHulya Ellidokuz
Hulya Ellidokuz

14 March 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MUMehmet Uzun
Mehmet Uzun
SGSavaş Gokcek
Savaş Gokcek
EKErhan Kaya
Erhan Kaya
HSHuseyin Salih Semiz
Huseyin Salih Semiz
Our study aimed to examine the predictive relevance of the Systemic Immune-Inflammation Index (SII) in patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 113 mCRPC patients were assessed. In this descriptive study, SII was calculated using the formula (neutrophil count × platelet count)/lymphocyte count. The optimal threshold for SII, determined via the ROC curve, was 700. Patients with SII ≤ 700 were classified as SII-low, while those with SII > 700 were categorized as SII-high. The median overall survival (mOS) was significantly longer in the low SII group compared to the high SII group (*P = 0.015). In multivariate analysis, Gleason score, albumin levels, CHAARTED volume, and SII were identified as significant prognostic factors. Our findings indicate that SII has a strong correlation with survival and can serve as an independent prognostic marker in mCRPC patients.

1 March 2023 in Future Oncology
Verified
Journal Article
Closed access
MKMerve Keskinkılıç
Merve Keskinkılıç
HSHuseyin Salih Semiz
Huseyin Salih Semiz
GPGul Polat
Gul Polat
Mehmet Emin ArayiciMehmet Emin Arayici
Mehmet Emin Arayici
TYTugba Yavuzsen
Tugba Yavuzsen
IOIlhan Oztop
Ilhan Oztop
Aims: The aim of this study was to evaluate the effect of prognostic nutritional index (PNI) on prognosis in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who rece... Plain language summary What is this article about? In cancer, in addition to known prognostic and predictive markers (e.g., age, performance status, clinicopathological features and disease stage),... Tweetable abstract The prognostic nutritional index (PNI) as a useful, simple and new prognostic indicator in patients with HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 i...

23 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
HEHalil İbrahim Ellez
Halil İbrahim Ellez
MKMerve Keskinkılıç
Merve Keskinkılıç
HSHuseyin Salih Semiz
Huseyin Salih Semiz
Mehmet Emin ArayiciMehmet Emin Arayici
Mehmet Emin Arayici
EKErdem Kısa
Erdem Kısa
IOIlhan Oztop
Ilhan Oztop
Background: In this paper, it was aimed to evaluate the biomarker potential as well as the effect of the prognostic nutritional index (PNI), which is calculated using the albumin level reflecting nutritional status and lymphocyte count reflecting immune status, in determining the prognosis of metastatic castration-sensitive prostate cancer (mCSPC). Methods: This retrospective observational study included the complete data of 108 patients with mCPSC who were treated for at least three months between January 1, 2010, and June 1, 2021. The relationship between cancer specific survival (CSS), overall survival (OS), progression free survival (PFS) and PNI was evaluated. Kaplan-Meier method for OS, PFS, and CSS, as well as univariate and multivariate Cox regression models were used in statistical analyses. Results: The median age of 108 patients included in the study was 68.54 (61.05-74.19) years. While 71.3% (n = 77) of the patient population were high-volume according to CHAARTED, 52.8% (n = 57) were high-risk based on LATITUDE. 49.75 was determined as the best cut-off point for the PNI. OS (months) was found to be significantly lower in patients with low PNI (median: 34.93, 95% CI: 21.52–48.34) compared to patients with high PNI (median: 65.60, 95% CI: 39.36–91.83) (p=0.016). Patients with high PNI (median: 48.20, 95% CI: 34.66–61.73) had significantly better CSS (months) than patients with low PNI (median: 27.86, 95% CI: 24.16–31.57) (p=0.001). Conclusions: PNI calculated at the time of diagnosis strongly predicts OS and CSS but not PFS in patients with mCSPC.